[Antibiotherapy in osteoarticular infections in children suffering from hemoglobinopathy in the University Teaching Hospital of Yopougon].
OBJECTIVE
The objective of this work was to evaluate antibiotherapy in osteo-articular infections found in children with henioglobinopathy, by identifying the antibiotics used and their mode of action. Their cost and efficacy were also assessed.


METHODS
The study was retrospective and it took place in the haematology unit, the paediatric surgical department and the central pharmacy of the University Teaching Hospital of Yopougon from 1991 through 1998. Thirty-two medical records of children, carriers of osteo-articular infections (OAI), were selected. Amongst these patients, most of whom had sickle-cell anaemia (97%), 50% were homozygous. Osteomyelitis represented 78% of these infections (salmonella infections being the most frequent cause, amounting to 35%).


RESULTS
Fifteen types of antibiotics amongst 57 from 5 families of drugs were used, with biotherapy (association of two drugs) being used in 69% of cases. The association of pefloxacine and netilmicine was the most frequently used and it was found to be the most expensive. The treatment was judged efficacious, with a satisfactory result in 75% of cases, based on the clinical criteria.


CONCLUSIONS
Bitherapy is the type of treatment, which is often of concern to many authors and relies on the general consensus surrounding the most likely emergency treatment of osteo-articular infections. Certain particularities are worth mentioning regarding this utilisation: the multiplicity of the molecules due to frequent rupture of hospital stock; the use of fluoroquinolones exceptionally prescribed in children under 15.


CONCLUSIONS
This antibiotherapy is justified owing to its efficacy on a sensitive issue concerning a pathology with grave sequellae, where long-term monitoring is necessary.
Aguéhoundé
Cosme
C
Service de chirurgie pédiatrique, CHU de Yopougon, 22 BP 1771, Abidjan, Cote d'Ivoire. agcosme@hotmail.com
da Silva
Sylvia Anoma
SA
Dieth
Attafi Gaudens
AG
Roux
Constant
C
Brouh
Yapo
Y
Sanogo
Ibrahim
I
Sangaré
Amadou
A
Agbodjan
Prince John
PJ
D000293:Adolescent; D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003365:Costs and Cost Analysis; D007560:Cote d'Ivoire; D005260:Female; D006453:Hemoglobinopathies / Q000150:complications*; D006801:Humans; D008297:Male; D010003:Osteoarthritis / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D010019:Osteomyelitis / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D012189:Retrospective Studies; D012737:Sex Factors; D013997:Time Factors
D000900:Anti-Bacterial Agents